pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Eylea
drug
save

Eylea

Marketedupdated 6mo ago
by $REGN REGENERON PHARMACEUTICALS, INC.
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval40 co-mentions · 15 sources
  • drugEYLEA HD32 co-mentions · 15 sources
  • drugaflibercept biosimilar15 co-mentions · 10 sources
  • drugYESAFILI14 co-mentions · 7 sources
  • drugOPUVIZ8 co-mentions · 4 sources
  • drugENZEEVU6 co-mentions · 3 sources
  • companySamsung Bioepis Co Ltd4 co-mentions · 4 sources
  • companySandoz Inc3 co-mentions · 3 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Eylea

  • phase2RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)completedn=139
  • phase3A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).recruitingn=514
  • phase3A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56active not recruitingn=400
  • phase2A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degenerationnot yet recruitingn=244
  • —An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)recruitingn=200
  • phase3CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEactive not recruitingn=240
  • phase3Aflibercept After Ranibizumab in Exudative Age-related Macular Degenerationcompletedn=84
  • phase3A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)recruitingn=960

News(10)

  • J&J bets $2.2B on Ollin’s vision loss drug
    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
    biopharma_dive · 20h ago
  • J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
    Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.
    fiercebiotech · 1d ago
  • Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
    AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.
    biopharma_dive · 14d ago
  • Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
    Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…
    biospace · 17d ago
  • EyePoint will halve workforce, end pivotal wet AMD trials early following second fail
    EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shiftin…
    biospace · 28d ago
  • This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
    The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
    biopharma_dive · 1mo ago
  • Lilly, Foghorn part ways; Wave’s FDA-approved plans
    The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
    biopharma_dive · 1mo ago
  • Kodiak skyrockets on positive study data for 2 eye drugs
    The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
    biopharma_dive · 1mo ago
  • Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
    Kodiak Sciences appears to have an Eylea successor on its hands. The Silicon Valley biotech said its experimental drug Zenkuda performed as well as Eylea in a progressive eye disease known as wet a…
    endpoints · 1mo ago
  • Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
    Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.
    biospace · 1mo ago
view all news mentions →
brand
Eylea
generic
aflibercept
indication
Diabetic Macular Edema
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 4m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?